SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical’s management team will participate in two October 2025 investor conferences. Details of the events are as fol ...

New “Picture Party by Myseum” next-gen social sharing platform with anti-AI protection technology expected to launch this fall NEW BRUNSWICK, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Myseum, Inc. (Nasdaq: MYSE) (“Myseum” or the “Company”), a privacy-first social media and technology company, today issued a shareholder letter by CEO Darin Myman detailing corporate progress, technology development, and the strategic roadmap for the new “Picture Party by Myseum” next-gen social sharing platform. Dear fellow sha ...

Brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, and sales growth Extensive track record in commercializing advanced laboratory testing and insurer strategies IRVINE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic solutions, today announced the appointment of Gary Huff to its Board of Directors as an independent board member. Mr. Huff brings decades of leadership experience in the diagnostics and heal ...

To Nasdaq Copenhagen A/S 8 October 2025 Announcement 87 /2025 Change of interest rate adjustment date for Jyske Rentetilpasning F1 Jyske Realkredit is changing the interest rate adjustment date for new offers of Jyske Rentetilpasning F1 (Private and Business) from January 1st to October 1st. The change will take effect from October 22nd, 2025. Questions regarding the bond sale as well as technical matters may be addressed to Jyske Realkredit, Lars Hasløv, Head of mortgage ALM tel. (+45) 89 89 92 19 or Chris ...

MORRISVILLE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its third FDA inspection, further affirming the quality and compliance of its Direct-to-Patient Site for clinical research. The inspection concluded with a No Action Indicated (NAI) categorization recommendation by the inspector, with no objectionable conditions noted and no Form 483 issued. The review centered on Science 37’s contribution in ...

Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners, a multi-family asset management firm based in Chicago, for consideration of up to $60 million in cash, consisting of an upfront payment of $45 million, and up to $15 million payable in the future upon the achievement of certain milestones. “This tran ...

RUTHERFORD, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Blue Foundry Bancorp (NASDAQ: BLFY) (the “Company”), the holding company for Blue Foundry Bank, announced that on the morning of Wednesday, October 29, 2025 it will release financial results for the quarter ended September 30, 2025. A copy of the earnings release will be available on the Company’s website, https://ir.bluefoundrybank.com/, in the “News” section and on the SEC’s website, https://www.sec.gov/. Representatives of the Company will hold a confer ...

VANCOUVER, British Columbia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Skeena Resources Limited (TSX: SKE, NYSE: SKE) (“Skeena Gold & Silver”, “Skeena” or the “Company”) is pleased to announce the closing of the previously announced bought deal offering of 5,991,500 common shares of the Company (the “Common Shares”), at a price of C$24.00 per Common Share (the “Offering Price”) for gross proceeds of C$143,796,000 (the “Offering”), which includes the exercise in full by the underwriters of their over-allotment optio ...

New platform module automates previous manual vaccine design processes, improving quality and dramatically reducing time and resource requirementsAI-Immunology™, already superior in vaccine target discovery, now also enables enhanced design applicable for both new vaccines and optimization of approved onesEvaxion will present detailed validation data on these improvements at the World Vaccine Congress Europe in Amsterdam on October 15, 2025 COPENHAGEN, Denmark, October 8, 2025 - Evaxion A/S (NASDAQ: EVAX) ...

ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the third quarter 2025 after the U.S. market close on Wednesday, November 5th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. E ...